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Roundthe caldrongo;
In thepoison'dentrails throw.
Toad, thatundercoldstone,
Daysandnights hastthirty-one
Swelter'd venom sleepinggot,
Boilthoufirst i'the charmedpot!
Macbeth (act IV, scene 1)
Shakespeare's witches realized that potions
contained marvelous concoctions ofingre-
dients (some obviously unattainable and
mythical in nature), several ofwhich could
alone elicit the coveted effect. This cele-
brated soliloquy reflects a unique knowl-
edge of hereditary folklore that particular
parts of animals and plants affect human
behavior (beliefs that continue in vogue
even as the twentieth century comes to a
close). In a sense, this witches' brew was a
cocktail of unknown chemical composi-
tion that could mimic and interfere with
human pharmacological responses (ago-
nists or antagonists that activate or block
pharmacological receptors leading to
changes at a physiological level, such as
stimulation or depression). Medicinal
chemistry is a recent outgrowth ofour his-
torical quest to define an active compo-
nent(s) from a host ofbiological sources-
plants, invertebrates, and vertebrates alike
(1-5)-much like modern chemistry arose
from alchemy.
Environmental mimicry is a "copycat
theme" (6) whereby organisms evolved to
resemble something innocuous or poisonous
as a defense against predation. Mimicry can
also be considered "adaptive convergence"
among different species living under similar
environmental conditions, such as adapta-
tion ofoceanicvertebrates (past andpresent)
with streamlined bodies and paddlelike
limbs or fins (7,8) and antigenic conver-
gence among phylogenetically diverse para-
sitic helminths in vertebrate hosts (9). In a
broader sense, mimicry includes coloration
(protective, obliterative, warning) and
"protective resemblance," chemical resis-
tance, and antigenic determinants (9). The
classic example that we associate with envi-
ronmental mimicry is "MUllerian mimicry"
(8), a well-known phenomenon amongst
lepidopterans; for example, moths that take
on the coloration and pattern of the bark
on which they alight ("industrial melan-
ism" is one such contemporary case) and
the deliciously edible Viceroy butterfly that
adopts the wing pattern of the unpalatable
Monarch butterfly. Aposematism (same or
a closely similar pattern shared by two or
more species) is encountered frequently
throughout the animal kingdom, and sev-
eral examples illustrate this phenomenon.
Among birds, three distinct species of
African birds (the flycatcher, cuckoo-
shrike, and tit) resemble the plumage ofthe
aggressive drongos, while in New Guinea
several species ofpitohui and a female ofan
unrelated species (a bird of paradise) take
on the colored plumage of the hooded
pitohui (5) which contains the toxic
homobatrachotoxin (a compound 500
times more potent than strychnine!) (10).
Tropical and neotropical amphibians exhibit
an abundance of mimicry in their striking
color combinations, many of which are
extremely poisonous (3). Reptilian mimicry
is also evident in the coloration and simi-
larity of the banding patterns between the
innocuous king snake and the deadly coral
snake. The semblance ofan Australian sea-
horse to its coral habitat affords protection
from predators.
Mimicry also occurs in distinct ways in
other species, most notably among insects:
the semblance of stick insects to dried
twigs, moth larvae to dried leaves, and leaf
insects to their habitat; some moths, bee-
tles, and flies have even "copied" the phys-
ical appearance ofvarious species ofpreda-
torywasps. Avariety ofplants, in their bid
for insect pollinators, mimic not only the
reproductive apparatus of other nonrelat-
ed species, but also physically resemble
insects (such as bees) to trick them into
mating with the plant in order to cover
them with pollen. Other plants, in the
Judean desert for example, acquire the red
color that attracts scarab beetles who, dur-
ing mating on the flower, carry away near-
ly 20 times more pollen than bees.
Naual ocring envirnntal substaces
often mimicendogenous substances found in
mammals andarecapableofinteractingwith
*. specific.proteins, such as receptors, with a
high degree of fidelity and selectivity.
Narcotic aids and amphibian ski secre-
tions, introduced into human society
through close association with plants and ;ials throughflk medicine and religious
divinatin prc':ices, wereinicorporatedi mto
the armaientarium ofthee early pharma-
copoeia. These skin secretions contain a
myriad of potent bioactive substances,
including aWkaoids, bioenic amines: pep-
tids eny, mus, Ad toxins (n us
compounds roewithistaiding); each class
exhibits a broad range ofcharacteristic prop-
erties. nx cific group ofpeptides, the
whopi..o g .h.ophins (drmal
morphinelike substances)and t deltor-
phins (selectiveopioidx display remark-
able analgesic properties and include an
amino aidl with the rae (in a mammalian
cont H-ai i liu of the dorm
LCisomer. tsis ofnrous stereospe-
cific analogues and conformational analyses
ofthese peptide provided essential insights
into the tiar composition and microenvi-
ronment of the rec pocket" nd' the
opia Intdcin beOre reeporan lig-
and that a biological response; new
advances nt-he synthesis and receptor-bind-
zing proper-ti'sof the dtorphins are dis-
W edw . inh recip:tr-spyec.f opi-
od pan mimics of
endogenouss opoiods: theirhigh selectivityfor
ether the p or receptormaksthem formi-
dabke enyIronmentaildeivd agents in the
addiction and in the treatment of wide
variety ofhuman disorders. Key words:
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This topic is not only fascinating to
evolutionary biologists and ecologists, but
also to biochemists, molecular biologists,
and toxicologists (1). When examined at
the molecular level, mimicry illustrates an
even more bewildering diversity and bizarre
theme of adaptation to a microenviron-
ment (6). The synthesis and secretion ofa
bevyofchemicals serve avariety ofpurposes:
attractants, for instance, in fungi or "fungal
pseudoflowers," which reproduce the taste
and odor of flowers to attract insects as
vectors in their transmission (6); repellents,
such as the toxic compounds associated
with the monarch butterfly, hooded pitohui,
and other organisms; camouflage, as beau-
tifully seen in the complete correspon-
dence, synthesis, and chemical identity of
larval hydrocarbons ofthe fly Microdon to
lull its obligate ant host/prey without set-
ting off alarm bells (2); and defense, as
depicted by the secretion of lethally toxic
compounds by certain amphibians onto
their skin in combination with vivid skin
coloration (1,3), thoroughly illustrated
among arthropods (11) and some plants
(12). These examples merely represent
some poignant illustrations of the use of
environmental chemicals, a phenomenon
aptly coined "chemical ecology" (5), to
mimic natural products found in one
species to bring about changes in other
nonrelated species. This implies dejure
that these extraneous substances interact
with endogenous receptor molecules to ini-
tiate a chain of intracellular signaling
events that elicit definable pharmacologi-
cal, biochemical, and physiological
responses. In fact, this concept of struc-
ture-activity relationships was elegantly
addressed by investigators over the past
two centuries who initially studied the
pharmacological properties of plant alka-
loids (13-15).
For millennia, human populations
throughout the world have turned to plant
materials (undoubtedly arising in the
search for food) and amphibian secretions
(1) to supply medicinal remedies and unc-
tions to counter pain (analgesia) and diar-
rhea (antiperistalsis), to produce euphoria
and a psychological sense ofwell-being, or
to induce religious hallucinations and div-
ination. For example, the Sumerians and
the early dynastic Egyptians, 6,000 and
4,000 years ago, respectively, used extracts
of Papaver somniferum in the treatment of
pain and diarrhea (16).
Amphibian skins, depending on the
genera and species, synthesize and secrete
an amazing diversity of compounds. Skin
secretions emanating from the granular
glands contain five major classes of sub-
stances, but not all in any one species of
amphibian (1,3,4): bufogenins (a family of
heterocyclic substances that inhibit K+/Na'
ATPase) (3); alkaloids (including the
major classes of dendrobatid alkaloids-
batrachotoxins, histrionicotoxins, indolizi-
dines, pumiliotoxin-A, and decahydro-
quinolines-and numerous minor classes-
gephyrotoxins, 2,6-disubstituted piperidines,
pyrrolidine alkaloids, pyridyl-piperidines,
indole alkaloids, azatricyclododecenes,
amidine alkaloids, epibatidine, saman-
darine alkaloids, morphine, tetrodotoxins,
and a group of miscellaneous piperidine-
based alkaloids), which collectively total
more than 200 compounds primarily from
toxic neotropic frogs of the genera
Dendrobates and Phyi1obates (3); biogenic
amines (consist of three distinct groups,
the indolealkylamines, imidazolealky-
lamines and phenylalkylamines, the latter
ofwhich includes common catecholamine
neuromodulators adrenaline, noradrena-
line, and dopamine) (4); peptides from 10
structurally and bioactively distinct families
(totaling over 100 peptides, ofwhich two-
thirds exhibit a broad spectrum of potent
biological activities in mammals and
include tachykinins, bradykinins,
caeruleins, bombesins, opioids, xenopsins,
thyrotopin-releasing hormone,
angiotensin, a heterogenous group of
amphiphilic peptides with antimicrobial
-activities, and a collection ofmiscellaneous
peptides and precursor fragments isolated
from Xenopus laevis) (1); and proteins or
proteinaceous components (such as
enzymes involved in a-amidation and
post-translational modification of peptides
including endo- and exopeptidases and
integumentary mucins, lectins, and toxins)
(1).
The habitual use ofmood-altering nar-
cotics often leads to addiction and drug
dependency (17), causes hypotension and
respiratory depression, and readily estab-
lishes the premise for considering molecu-
lar mimicry: a potential requirement for
highly specific complementary interactions
between a ligand and its receptor involves
stereochemical configuration, spatial con-
formation, and functional groups necessary
for association (18). Establishing a function
for newly discovered classes ofopioid com-
pounds' (4) provides the key to unraveling
the mysteries ofthe opioid receptor.
In an evolutionary context, we might
ask ourselves why we would expect to find
environmental opioids to mimic endoge-
nous substances and interact with mam-
malian receptor molecules. (Environmental
estrogenic compounds that mimic mam-
malian steroids and bind with steroid
I1n this paper we wish to emphasize a differentia-
tion in the use ofthe terms "opioid" and "opiate."
The former denotes only peptides and the latter
alkaloid (or nonpeptide) substances that exhibit
morphinomimetic analgesia.
receptors are coming to the forefront in
research on human disease and animal
biology.) Have not mammals evolved in
divergent directions for the past 230-255
million years from their amphibian ances-
tors or over an even greater time span from
the experimental prototypes of life in the
Cambrian and Proterozoic eras (two bil-
lion distant years past) that eventually gave
way to our extant phyla? What could be
the basis for molecular mimicry or the sta-
bility of receptor recognition mechanisms
since the origin of protozoans, such as
Tetrahymena, which has opioid receptors
(19,20)? Could the protozoan 5 receptor
type be the archaic progenitor for p and K
receptors based on the degree of sequence
similarity among them by evolving (21)
through various genetic mechanisms
(mutation, gene duplication, genome
rearrangement) (1)? We knowthat primitive
neuronal systems (nerve networks) were
not in place until the emergence of early
metazoans; therefore we can surmise that
opioid substances functioned differently
than is assumed today. Hypothetically, an
opioid receptor might have arisen in
response to nutritional requirements (22),
regulated ionicconductance (23), oraffected
reproduction long before a neuromotor
system evolved per se. Interestingly, if one
considers that "the underlying mechanism
for neural activity is ionic" (24), then the
ability of opioid peptides to modulate ion
flux and adenyl cyclase activity suggests
that the protozoan receptors might be
preadapted to function in the control of
ionic conductance when they became
eventually located in a potential neuronal
membrane through evolution.
Opioids and their receptors play vital
roles in the overall homeostasis of mam-
malian physiology. The major attributes of
opioid action in vertebrates can be briefly
condensed as production of analgesia;
modification ofthe secretion ofcirculating
peptide hormones; alteration ofbody tem-
perature; constriction ofthe pupil; depres-
sion of respiration and gastrointestinal
function (acting as an emetic); involve-
ment with the cough response; enhance-
ment of peripheral vasodilation; and asso-
ciation with the immune system (25).
Thus, in spite of the accumulation of
mutational changes (the basis ofhereditary
variability), the maintenance of molecular
mimicry in the opioid peptide-receptor
relationship points to a highly stable sys-
tem ofinteracting components.
One possible reason for the presence of
a high concentration ofopioids among the
vast quantities ofbioactive peptides secret-
ed by the genus Phyllomedusa (26) could
be an amphibian defense network (simply
described as "overkill") (1): predators
evolve means to circumvent "even the most
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novel defense" (3); opioids represent a class
of substances whose wide spectrum of
activity provides another bastion ofprotec-
tion. The production and secretion oflarge
amounts ofbioactive substances is a further
indicator of the amphibian environment:
animals, such as frogs, who spend a por-
tion oftheir time in aqueous environs will
need higher concentrations of skin secre-
tions due to dilution and persistent wash-
ing of their integuments by the water. By
analogy, this would be like treating a
microbial infection simultaneously with
several general-acting antibiotics to ensure
possible elimination of the causative
agents. And like the excessive application
of antibiotics, which leads to resistant
organisms, amphibian predators evolved
means to cope with the compounds in skin
secretions and, in turn, the need for the
production ofmore diverse compounds by
amphibians.
Opioid Substances
The most commonly identifiable environ-
mental chemicals of social concern-rela-
tive to opioid peptides-are the narcotic
alkaloids, promulgated in the news media
and governmental policy through the "war
on drugs." Morphine (named after the
Greek god of dreams, Morpheus), first
crystallized in 1803 as a constituent of
opium (13), triggers a biochemical response
due to the complimentarity of its ring
structure with the microenvironment
(internal shape, ionic and hydrophobic
milieu) ofthe receptor. The salient feature
ofthe pharmacological effects ofthe opiate
alkaloids, determined by the synthesis of a
vast array of related drugs, is their high
degree of stereoselectivity (14), analogous
to that observed with the amphibian opi-
oid peptides (27). In the case of the alka-
loids, however, their affinities for the opi-
oid receptors are relatively low-being
orders of magnitude less than that of the
endogenous enkephalins (16,28) or exoge-
nous amphibian opioids (29).
The discovery of the enkephalins (30)
and P-endorphin two decades ago (Table
1) explosively opened a new field in neuro-
science. Theygenerated interest in the rela-
tionship between opioids and the immune
system (31-34) and continue to make
headlines as /endorphin is the supposed
endogenous hormone released upon stren-
uous exercise (the body's elixir to adapt to
physical strain and stress).
A seminal change (and a most fortu-
itous modification as discussed further in
this commentary) in the concept ofopioid
structure occurred through the introduc-
tion of the D-enantiomer of alanine in
place of glycine at the second position
(Table 1) of a synthetic enkephalin pep-
tide; this produced an analogue with pro-
Table 1. Sequences of naturally occurring opioid peptides
Peptide
Mammalian
Enkephalins
I3-Endorphinb
Dynorphinsc
Dynorphin A
Dynorphin B
P-Neo-endorphin
Amphibiand
Dermorphins
Deltorphins
Sequence
Tyr-Gly-Gly-Phe-Leu
Tyr-Gly-Gly-Phe-Met
Tyr-Gly-Gly-Phe-Met-Arg-Phe
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-
Asn-Ala-lle-lle-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-
Asn-Ala-Tyr-Tyr-Glu-Glu-Leu-Phe-Asp-Val
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
Tyr-o-AAa-Phe-Gly-Tyr-Pro-Ser-NH2
Tyr-D-Ala-Phe-Gly-Tyr-Hyp-Ser-NH2
Tyr-D-Ala-Phe-Gly-Tyr-Hyp-Ser
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Lys
Tyr-D-Ala-Phe-Trp-Tyr-Pro-Lys
Tyr-D-Ala-Phe-Trp-Asn
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-Gly-Glu-Ala
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-Gly-Glu-Ala-Lys-Lys-lle
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 (A)
Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (B)
Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (C)
Tyr-o-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-lle-Gly-Asp-Phe-Phe-His-Ser-lle-NH2
aAmino acid residues in bold indicate differences with the parental peptide beginning each section.
Unless specified, the C-termini contain a free carboxylic group (-COOH). All the mammalian peptides con-
tain the identical N-terminal tetrapeptide sequence (Tyr-Gly-Gly-Phe), whereas the amphibian peptides
are characterized by a D-enantiomer at position 2 of a commontripeptide sequence (Tyr-D-Xaa-Phe).
bThe ,B-endorphin family consists of three peptides: a-, P-, and y-endorphin, which are derived from the
precursor protein, proopiomelanocortin. P-Endorphin contains the sequences of [Met5]enkephalin (I-
endorphin 1-5), a-endorphin (0-endorphin 1-16) and y-endorphin (3-endorphin 1-17), the latter two repre-
sent either degradation Iroducts or processed fragments. Although P-endorphin and the dynorphins con-
tain the [Met ]- or [Leu enkephalin sequence, neither one are the precursors for these opioids (14,75).
The sequence ofP-endorphin shown isthatfrom camel.
CThe structural similarity among the dynorphin family resides in residues 1-6. A commonly occurring
dynorphin isthe N-terminal octapeptide fragment, dynorphin A 1-8 (Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle).
1the lattertwo dermorphin peptides were isolated, but representfragments generated fromthe precursor
before subsequent proteolytic cleavage and formation of the C-terminal amide from glycine by an
enzymic a-amidation reaction (1). Smaller synthetic fragments of [D-Leu2jdeltorphin, sequences 1-10 and
1-7, weakly interactwith 8 and p opioid receptors but are nonselective (44).
longed bioactivity (35,36) due to
enhanced stability against proteolytic
degradation (35). Literally, many hun-
dreds of enkephalin analogues have been
synthesized (37) based on this singularly
important observation. Although the
announcement in 1980 ofa potent opioid
peptide from amphibian skin (38), der-
morphin, triggered considerable consterna-
tion (that a rare D-amino acid should be
found in organisms other than bacteria,
mold, and algae) (1), it should have been
anticipated by the science community
from the extensive body of literature on
enkephalin analogues (37). By the end of
the decade, another group of D-amino
acid-containing opioid peptides was dis-
covered from the same amphibian source
(38-40)-the deltorphins, opioid peptides
with the highest affinity and selectivity for
6 opioid receptors (40-43), except the
larger D-Leu-containing variant which is
essentially devoid of both 6 and p activity
(44). Amphibian opioid peptides are not
recognized by the mammalian K receptor,
the third distinct opioid receptor that
binds the dynorphin family ofopioid pep-
tides (37) (Table 1). In spite oftheir limit-
ed size (a heptapeptide is small by most
biochemical standards), it was proposed that
the N- and C-terminal regions represented
the common "message" and specific
"address" domains, respectively (patterned
after the model established for discrete sec-
tions of the adrenocorticotropin hormone
molecule) (45).
An intriguing feature of the precursor
proteins for opioid peptides, regardless of
their biological source, is the existence of
the coding for multiple bioactive peptides
within a single genomic transcript
(16,39,40,46). As a comparable example,
the enkephalin prohormone precursor con-
tains seven copies ofbioactive peptide (47)
(Fig. 1), which are excised by the action of
specific proteolytic enzymes acting at
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[Met5JEnkephalin [Leu'lEnkephalin
[Met5,ArdsGl7 Leul - IMets
Enxephaln ~~Enks
Preprodynorphin (256)
[LeusArg,Leu7,ProJ -
Enkephalin
ePhe'] asphalin
Dynorphins
A B
CAOG=Z
Preprodermorphin (197)____ Prprd i (197Identical 35 anino acid repeats -
Dernorphin
Deltorphin A
Preprodeltorphins 8/C (227) TlTr--Ala-Phe- Identical 36 amino acid repeats
Gy-Tyr-Pro-Lys . 1
Tyr-D-Ala-Phe- Deltorphin B + * 4
Trp-Tyr-Pro-Asn Deltorphin C
Figure 1. Diagrammatic structures of the preprohormones of enkephalin, fB-neo-endorphin/dynorphin,
dermorphin, deltorphin A/dermorphin, and deltorphins B and C/dermorphin analogues. The numbers in
parentheses are the number of amino acid residues in the transcribed protein; the precursors are each
drawn to scale. An interesting feature ofthe amphibian preprohormone is the greater use ofthe precur-
sor protein; the tertiary structural features of the homologous repeat sequences may be involved in the
inversion of the stereo configuration from Lto D atthe a-carbon of residue 2 of the bioactive peptide (1).
The boxed regions indicate the presence of a potential opioid peptide; the stippled areas indicate preva-
lent bioactive peptides or sequences of direct homology for a given precursor. The solid line is the
remainder ofthe precursor protein; in both the dermorphin and deltorphin prohormones,the narrow open
bar denotes homologous sequences within the respective protein.
Figure 2. Structure of 6 and p opioid receptors. Each sphere in the chain represents an amino acid: the 8
receptor-specific residues are blue, those for the p receptor are yellow, and those common to both
sequences are green; the branched structures represent presumed complex carbohydrate on threonine
residues. The light shaded band depicts the cell membrane with the extracellular space above denoted
bythe common N-terminus (-NH2) and the intracellular compartment belowwith the C-termini (-COOH).
paired dibasic residues. Similarly, both molecule (16). The dermorphin precursor
dynorphins A and B exist in a single pro- also contains multiple copies of the func-
hormone along with P-neo-endorphin tional bioactive peptide within interesting
(48; however, even though [Leu5]enkephalin homologous 35 amino acid repeats that,
comprises the amino terminal pentapep- based on their primary sequence, would
tide in these peptides (48) and appear to form distinct a-helixes.
[Met ]enkephalin occurs in f-endorphin However, the genomic information codes
(47), these larger opioids are not further for the normal L-isomer of alanine, there-
processed to the level of the enkephalin fore indicating that the conversion to the
D-enantiomer might represent either a
novel post-translational modification in
frog skin (39) or some other inversion
mechanism (1,49,50). One cDNA clone
ofa dermorphin preprohormone contained
the sequence ofdeltorphin A (39), while in
the case ofdeltorphins B and C, the cDNA
transcripts included one copy ofdeltorphin
B and from zero to three copies ofdeltor-
phin C (40), as well as two new dermor-
phin-related peptides (Fig. 1). The multi-
plicity ofbioactive peptides in a single pre-
cursor prohormone suggests the require-
ment ofa temporal change-"fecundity"-
that denotes either the high turnover of a
labile product or the necessity for vast
quantities of peptide to oversaturate the
immediate vicinity of the amphibian with
bioactive molecules. Remarkably, amphibian
skins, for example, have the unique capaci-
ty to produce and secrete relatively high
percentages of peptide in relation to the
wetweight oftheir skins (4,26,29).
The presence of exogenous (environ-
mental) opioid peptides clearly indicates
that the mammalian opioid receptors
retained a unique tertiary conformation
during evolution in spite of differences in
their sequences (51-59) (Fig. 2). The com-
bination of sequence and receptor confor-
mation enables them to selectively screen
and bind peptide ligands which exhibit
close structural similarity. A remarkable
degreeofsequence conservation in theopioid
receptors is seen in the seven transmem-
brane regions (Fig. 2); the majority ofdif-
ferences reside, however, in the N-terminal
domain and one extracellular loop (exclud-
ing the variability seen in the intracellular
C-terminal portion) that could be respon-
sible for the difference between binding of
receptor-selective agonists and antagonists,
or compounds that exhibit partial agonist
and antagonist activity.
Molecular Models
The one invariable characteristic of the
opioid peptides is a hydroxyl group on the
N-terminal side chain oftyrosine, which is
essential for opioid activity (28,3X; inter-
estingly, this side chain resembles the
hydroxylated aromatic ring of the rigid
alkaloid opiates. Shortly after the discovery
of the enkephalins, structural models
appeared that attempted to explain the
interaction ofthe opioids with their recep-
tors by simply superimposing the opioid
on the ring structure and charged centers
of the narcotic alkaloids (28,60-62), in
spite of the X-ray diffraction analysis of
enkephalin crystals which detailed the
presence of a n-turn in the N-terminal
region (62). Application of 1H-NMR to
study the topography of dermorphin and
the deltorphins (63-65) revealed a strong
propensity for these molecules to acquire a
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Figure 3. Molecular dynamics models ofthe deltorphins: (left), deltorphin A, deltorphin B, and (right) del-
torphin C (see Table 1 for sequences) depicted with space-filling models. Magenta indicates the back-
bone, cyan the carbons of the side chains, purple the nitrogens (in histidine and amide groups), yellow
the sulfur atoms (in the methionyl residues), and red the oxygen atoms.
type II' n-turn in solution in the N-termi-
nal tripeptide region with type I n-turns in
the C-terminal domain as seen in deltor-
phin (65). These physicochemical data
provided the rationale for the essential
importance ofthe D-isomeric spatial orien-
tation ofthe residue at position 2, and the
backbone and side-chain dihedrals (torsion
angles) of these peptides. Studies on the
bioactivity (pharmacological preparations
in vitro and production of analgesia in
vivo) and receptor binding confirmed the
absolute requirement of the D-enantiomer
at position 2 since the stereo inversion
around the a carbon to yield an L-isomer
reduced opioid activity by several orders of
magnitude (27,29).
The advent of computer modeling in
combination with the intrinsic values for
backbone and side-chain torsion angles
derived from 'H-NMR spectroscopy and
NOESY (nuclear Overhauser effects spec-
troscopy) led to multiple model structures
for enkephalin analogues (66,67). This
method further provided the first direct
correlation between the solution conforma-
tion of the flexible (non-constrained) del-
torphins and receptor binding data (68).
The solution conformation of the deltor-
phins, as seen in Figure 3, illustrates the
topography of a peptide with the highest
probability of binding in the receptor
"pocket" at a specific receptor subsite; that
is, deltorphin B interacts in a heteroge-
neous manner best described as fitting a
two-site binding model (which may be
equivalent to the 62 receptor subtype),
while the binding ofdeltorphins A and C
(61 receptor ligands) are classically defined
as interacting by means ofa simple, bimol-
ecular one-site model (73). With the emer-
gence of a predictive means to propose
active peptide conformations combined
with a knowledge oflow-energy conforma-
tions (although it should be pointed out
that the lowest energy conformation may
not necessarily be biologically active), we
systematically synthesized several hundred
deltorphin analogues (and an equivalent
number of dermorphin analogues) using
solid-phase and solution methods
(27,64,69-74). Thus, we were able to
apply these amphibian opioid analogues as
highly selective molecular probes to eluci-
date binding to selective receptors and to
further differentiate between pharmacolog-
ically defined receptor subtypes (72,73).
Owing to the recent interest in the
pharmacology of the deltorphin family of
peptides, we highlight andbrieflysummarize
the major chemical characteristics of these
remarkable opioid peptides (Table 1), pri-
marily determined in receptor binding
studies with rat brain membranes (synapto-
somes). 1) The properties ofthe side chain
ofthe residue at position 4 enable the hep-
tapeptide to differentiate between 6 and p
receptors through influencing its affinity
toward p receptors; that is, whereas 6 affin-
ity remains relatively constant, the p bind-
ing constants may fluctuate by two orders
ofmagnitude. Moreover, residue 4 enables
the peptide to discriminate between specific
receptor subsites (based on statistically
valid binding models) (72,73) that may
reflect pharmacologically defined receptor
subtypes (73). In deltorphin A, for
instance, the imidazole (His4) side chain is
crucial for the expression ofhigh 6 affinity
(27,69).
2) The ionizable anionic side chains
play a minor role in 6 receptor affinity. On
the other hand, 6 selectivity is nevertheless
markedly enhanced because the acid func-
tion suppresses interaction with p receptors
(70,71); cations are detrimental for deltor-
phin-mediated binding. 3) Hydropho-
bicity, centered either at the fifth residue or
in the composite nature ofthe lipophilicity
ofthe C-terminal region, directly affects 6
affinity (71,73-76). [Similarly, the binding
ofdermorphin to p receptors was enhanced
by the presence ofadditional hydrophobic
substituents (77).] 4) Deltorphin hep-
tapeptide and abbreviated analogues con-
taining an unnatural bicyclic-constrained
amino acid in position 2 were surprisingly
active (78-82). For example, the dipeptide
Tyr-Tic-NH2 represents the smallest pep-
tide recognized by the S opioid receptor
and may represent the universal opioid
"message" domain (82). Furthermore, the
subtle change in chirality from L- to D-
stereoisomer at position 2 in both di-
(82,83) and heptapeptides dramatically
switches the selectivity from one receptor
type to the other. The systematic change to
the D-stereochemistry of each individual
residue in deltorphin A provided addition-
al evidence that proper spatial orientation
is necessary within the N-terminal pen-
tapeptide region (27). (These combined
observations represent one essential key to
ferreting out the precise milieu, internal
binding interactions, and structure of the
receptor pocket.)
5) In our continuing exploration of
replacement analogues using unnatural
amino acids in the N-terminal sequence of
deltorphins, we obtained peptides which
exhibit either super 6 receptor selectivity
properties or have equivalent high affinities
for both 6 and p receptors (73, unpub-
lished observations). These unusual opioid
peptides, as well as the di- tri-, and
tetrapeptides (80-82), apparently produce
a unique low-energy conformation in solu-
tion to fit unobtrusively (yet with great
fidelity) into the 6 receptorwith exceptional
selectivity (82,83, Bryant et al., unpub-
lished observations). These data simultane-
ously invalidate opioid models in which
opioid peptides were merely superimposed
on the rigid rings ofmorphine (60-62).
Conclusions
The case for amphibian peptides as environ-
mental opioids (or morphinomimetic sub-
stances) has singular importance as highly
specific endogenous ligands acting on
mammalian opioid receptors and is indeed
quite compelling and substantiated by an
enormous body of scientific evidence. To
partially answer the questions posed (supra
vide), at least two possible theories can
account for the molecular mimicry of
amphibian skin opioids for mammalian
opioid receptors: 1) The opioid peptides
could have evolved by convergent evolu-
tion to the endogenous peptides associated
with vertebrate tissues. This idea stems
from the concept of the "brain-gut-skin
triangle" proposed by Erspamer (43,84)
that states that peptides occurring in
amphibian skin appear to exist in a similar,
if not identical sequence, in mammalian
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brain and gut; and 2) opioid peptides in
skin secretions originally were used for dif-
ferent purposes by amphibians (and other
forms of life) and acquired new functions
over time (1). Thus, the opioids and their
receptors have remained unchanged since
the evolution of unicellular organisms due
to the acquisition of a neuromodulator
role. Ofcourse, other theoretic alternatives
exist to answer this tantalizing question,
and only extensive experimentation with
these remarkable compounds and their
receptors will lead us toward more defini-
tive conclusions.
The conservation of opioid peptides
and receptors during evolution implies a
"physiological function that confers a selec-
tive advantage on the organism" (85).
Whether that function can be solely attrib-
uted to analgesia (85), however, remains
an open question. During the early, forma-
tive period in evolution, opioids and opioid
receptors presumably arose simultaneously
(1,22) and were conserved thereafter in
response to basic mechanisms of life: eat,
survive, and reproduce. Excellent examples
ofthis dictum can be found in the effect of
opioids/opiates on protozoans: in
Paramecium, the regulation ofion channels
affects the direction of ciliary movement
(23,24), which would propel it toward a
food source or away from danger; in
Tetrahymena, a reduction motility is noted
(86) as well as the inhibition ofphagocyto-
sis (20), which would affect nutrient
uptake. Thus, we might ask a further ques-
tion: could opioid analgesia be a secondary
manifestation of calcium regulation (or
being undernourished for unicellular organ-
isms; in otherwords, antagonism ofmolec-
ular satiety) and with the evolution ofmul-
ticellular organisms became associated with
neurophysiological functions?
The study of amphibian opioid pep-
tides as environmental chemicals that
mimic endogenous mammalian substances
affords us an excellent opportunity to
selectively probe receptor molecules that
are relevant in human health and disease.
Furthermore, from their basic structure
may eventually spring synthetic analogues
to assist in the fight against the perennial
problem of opiate addiction and many
other equally valid health-related issues
(alcoholism, neurological diseases, psycho-
logical abnormalities triggered by neuro-
transmitter imbalance and neurological
dysfunctions, post-operative pain, memory
loss in trauma victims and epileptic seizures,
acute and chronic pain associated with ter-
minal cancer, and prevention ofgraft rejec-
tion). In fact, many laboratories have initi-
ated projects to further enhance the inher-
ent in vitro stability and chemical proper-
ties of opioids to optimize their passage
through the intractable blood-brain barrier
that would enable them to function as
highly selective antagonists to relieve nar-
cotic dependency and perhaps attenuate
the psychopathological conditions ofschiz-
ophrenia, depression (85), and Tourette's
syndrome (87).
After millennia of being maligned,
feared, and grossly misunderstood, frogs
(and toads) might continue to bolster the
well-being of human society-if they sur-
vive the detrimental onslaught of the
effects ofenvironmental pollutants (1,88).
The fate of amphibians and humans are
inexorably intertwined. The eons of
amphibian existence and the brevity of
humankind could be summed up by a
quote from Shakespeare (89): "The oldest
hath borne most: we that are young shall
never see so much nor live so long."
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